Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Nephrotoxic potential of selective cyclooxygenase-2 inhibitors.

Sandhu GK, Heyneman CA.

Ann Pharmacother. 2004 Apr;38(4):700-4. Review.

PMID:
14982980
2.

Use of NSAIDs for the chemoprevention of colorectal cancer.

Herendeen JM, Lindley C.

Ann Pharmacother. 2003 Nov;37(11):1664-74. Review.

PMID:
14565811
3.

The cyclooxygenase-2 inhibitors: safety and effectiveness.

Kaplan-Machlis B, Klostermeyer BS.

Ann Pharmacother. 1999 Sep;33(9):979-88. Review. Erratum in: Ann Pharmacother 1999 Dec;33(12):1376.

PMID:
10492503
4.

Renal effects of cyclooxygyenase-2-selective inhibitors.

Brater DC.

J Pain Symptom Manage. 2002 Apr;23(4 Suppl):S15-20; discussion S21-3. Review.

PMID:
11992745
5.

Cyclo-oxygenase 2 inhibitors: emerging roles in the gut.

Grover JK, Yadav S, Vats V, Joshi YK.

Int J Colorectal Dis. 2003 Jul;18(4):279-91. Review.

PMID:
12774242
6.
7.

Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors.

Komers R, Anderson S, Epstein M.

Am J Kidney Dis. 2001 Dec;38(6):1145-57. Review.

PMID:
11728945
8.
9.

Reducing clinically significant gastrointestinal toxicity associated with nonsteroidal antiinflammatory drugs.

Jacobsen RB, Phillips BB.

Ann Pharmacother. 2004 Sep;38(9):1469-81. Review.

PMID:
15213313
10.

Cyclooxygenase-2 inhibitor-associated acute renal failure: case report with rofecoxib and review of the literature.

Morales E, Mucksavage JJ.

Pharmacotherapy. 2002 Oct;22(10):1317-21. Review.

PMID:
12389882
11.

Effect of cyclooxygenase-2 inhibitors on blood pressure.

Johnson DL, Hisel TM, Phillips BB.

Ann Pharmacother. 2003 Mar;37(3):442-6. Review.

PMID:
12639178
12.

Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events.

Mukherjee D.

Biochem Pharmacol. 2002 Mar 1;63(5):817-21. Review.

PMID:
11911832
13.

Clinical pharmacology of novel selective COX-2 inhibitors.

Tacconelli S, Capone ML, Patrignani P.

Curr Pharm Des. 2004;10(6):589-601. Review.

PMID:
14965322
14.

Cyclooxygenase-2 inhibitors: promise or peril?

Mengle-Gaw LJ, Schwartz BD.

Mediators Inflamm. 2002 Oct;11(5):275-86. Review.

15.

Osteoarthritis therapy--are there still unmet needs?

Laufer S.

Rheumatology (Oxford). 2004 Feb;43 Suppl 1:i9-15. Review.

16.

The therapeutic potential of NO-NSAIDs.

Wallace JL, Del Soldato P.

Fundam Clin Pharmacol. 2003 Feb;17(1):11-20. Review.

PMID:
12588626
17.

The COX-2 inhibitors: new analgesic and anti-inflammatory drugs.

Khan AA, Dionne RA.

Dent Clin North Am. 2002 Oct;46(4):679-90. Review.

PMID:
12436824
18.
19.

Nonsteroidal anti-Inflammatory drugs and cardiovascular risk.

Howard PA, Delafontaine P.

J Am Coll Cardiol. 2004 Feb 18;43(4):519-25. Review.

20.

Renal effects of cyclooxygenase-2 selective inhibitors.

Harris CJ, Brater DC.

Curr Opin Nephrol Hypertens. 2001 Sep;10(5):603-10. Review.

PMID:
11496053
Items per page

Supplemental Content

Support Center